📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-21 17:21
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
17 announcements match the current filters (relevance ≥ 5).
43% YoY Revenue Growth in Q1 FY27; First Semiconductor Batch Qualified
Tatva Chintan reported a strong Q1 FY27 with operating revenue of Rs 167.1 Cr, a 43% YoY increase, and EBITDA growth of 86% YoY to Rs 32.3 Cr. A major milestone was achieved with the successful qualification of the first commercial batch for the semiconductor industry, a high-entry-barrier segment. While the Structure Directing Agents (SDA) segment grew 47% YoY driven by Euro 7 standards, Electrolyte Salts saw a 52% sequential dip due to Middle East supply chain disruptions. Management has adjusted long-term asset turn expectations to 1.5x due to complex chemistries but is targeting a healthy 20-22% ROIC.
Confidence: HIGH
What changedThe company has successfully transitioned its first semiconductor product from pilot to commercial qualification and is seeing a recovery in SDA demand.
Why it mattersEntry into the semiconductor chemical space and the scaling of Euro 7-compliant SDAs represent a shift toward higher-value, technologically complex products with higher entry barriers.
Q1 FY27 Revenue: Rs 167.1 CrYoY Revenue Growth: 43%EBITDA Growth: 86%SDA Revenue Growth: 47%Target ROIC: 20-22%Q1 Revenue vs TTM Revenue: 33.7%
📅 Short termThe strong YoY growth and breakthrough in the semiconductor segment are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe shift toward complex Pharma, Agro, and Semiconductor intermediates may lead to lower asset turns but offers a path to sustainable 20%+ ROIC and reduced cyclicality.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Raw material supply disruptions due to geopolitical issues
- Chinese price competition in commodity-like chemicals
- Long validation cycles for semiconductor products
Key Highlights
Q1 FY27 revenue reached Rs 167.1 Cr, a 43% YoY growth and 25% sequential increase.
EBITDA grew 86% YoY to Rs 32.3 Cr, reflecting improved operational leverage.
SDA segment revenue rose 47% YoY to Rs 57.8 Cr, benefiting from Euro 7 implementation.
First commercial batch for the semiconductor industry was qualified, with 5 products currently in the pipeline.
Management targeting 20-22% ROIC despite lower asset turns of 1.5x due to multistage chemistries.
👀 What to Watch
Watch for the commercial ramp-up of the semiconductor segment and the resolution of raw material supply issues in the Electrolyte Salts business in upcoming quarters.
Tatva Chintan Commences Construction of New Greenfield Unit at Dahej-III
Tatva Chintan Pharma Chem Limited held its groundbreaking ceremony (Bhoomi Pujan) for a new greenfield manufacturing unit at Dahej-III on July 20, 2026. This expansion follows a recent capacity increase from 160 KL to 280 KL and is designed to meet growing market demand for specialty chemicals. While the specific capex and capacity for this new unit were not disclosed in the filing, it aligns with the company's 27% expected growth rate. The project is a key component of the company's strategy to leverage its R&D and expand its global footprint across 30+ countries.
Confidence: HIGH
What changedThe company has officially moved into the physical construction phase of a new greenfield manufacturing facility at Dahej-III.
Why it mattersThis expansion is critical for scaling the business beyond its current 280 KL capacity to support long-term revenue growth and market share in the high-margin SDA and PTC segments.
Current aggregate capacity: 280 KLPrevious aggregate capacity: 160 KLTTM Revenue: ₹496 CrExpected growth rate: 27%Ceremony Date: 20 July 2026
📅 Short termThe announcement is sentimentally positive, signaling management's confidence in future demand despite recent margin volatility.
📈 Long termStructurally significant; greenfield expansions are the primary drivers for scaling specialty chemical businesses and typically contribute to revenue over a 2-4 year horizon.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk (construction delays)
- Capital intensive nature of greenfield projects
- Potential for initial margin dilution due to high fixed costs
Key Highlights
Groundbreaking ceremony (Bhoomi Pujan) for the new greenfield unit held on July 20, 2026.
New facility is located at Dahej - III, Dahej Industrial Estate, Gujarat.
Expansion follows a prior capacity increase from 160 KL to 280 KL across 13 assembly lines.
Project supports the company's target growth rate of 27% and FY26 product commercialization plans.
👀 What to Watch
Monitor upcoming quarterly presentations for specific details on the capex outlay, planned capacity of the Dahej-III unit, and the expected commissioning timeline.
140% PAT Growth in Q1 FY27; Revenue up 43% to ₹167.1 Cr
Tatva Chintan reported a strong start to FY27 with Q1 revenue growing 43% YoY to ₹167.1 Cr, significantly outpacing the previous year's performance. EBITDA margins expanded to 19% from 15% YoY, resulting in an 86% jump in EBITDA to ₹32.3 Cr. Net profit surged 140% YoY to ₹16.0 Cr, reflecting a sharp recovery from the low base of FY25. The company is now leveraging its expanded 791 KL capacity, with the PASC segment contributing 35% of the quarterly revenue mix.
Confidence: HIGH
What changedThe company has moved from a period of earnings contraction in FY25 to high double-digit growth in Q1 FY27, supported by a significant capacity increase to 791 KL.
Why it mattersThe sharp recovery in margins and profitability suggests that the company is successfully achieving operating leverage from its recent capital expenditures and diversifying its product mix.
Q1 FY27 Revenue: ₹1,671 MnQ1 Revenue vs TTM Revenue: ~33.7%Q1 FY27 PAT Growth (YoY): 140%EBITDA Margin: 19%Total Installed Capacity: 791 KL
📅 Short termThe stock is likely to react positively to the strong YoY and QoQ growth in both revenue and profitability, indicating a turnaround from previous quarters.
📈 Long termThe structural expansion to 791 KL capacity and diversification into PASC and Electrolyte Salts (ESS) positions the company for higher scale, though global demand for SDAs remains a key variable.
⚠ Risk flags
- High valuation with a P/E of 78.9
- Global demand sensitivity for SDA products
- Raw material price volatility
Key Highlights
Q1 FY27 Revenue increased 43% YoY to ₹1,671 Mn compared to ₹1,169 Mn in Q1 FY26.
Net Profit (PAT) grew 140% YoY to ₹160 Mn, with PAT margins improving to 10% from 6%.
EBITDA (excluding other income) rose 86% YoY to ₹323 Mn, with margins reaching 19%.
Total manufacturing capacity reached 791 KL with 39 assembly lines as of March 31, 2026.
The PASC segment (Pharma & Agrochemical Intermediates) now accounts for 35% of revenue, up from 32% in FY26.
👀 What to Watch
Monitor the utilization levels of the expanded 791 KL capacity and the sustainability of margins in the SDA segment, which is historically high-margin but volatile. Watch for continued growth in the PASC segment as a diversifier against SDA demand fluctuations.
Rs 200 Cr Greenfield Expansion; 344 KL Capacity Addition; Q1 Standalone PAT up 103% YoY
Tatva Chintan has approved a major greenfield expansion at Dahej-III, adding 344 KL of reactor capacity, which represents a 122% increase over its current 280 KL capacity. The project requires an investment of ~Rs 200 Cr (approx. 40% of TTM revenue) and is expected to be completed within 21 months. Alongside this, the company reported strong Q1 FY27 results with standalone revenue up 34% YoY to Rs 146.7 Cr and PAT doubling to Rs 10.45 Cr. To support this growth, the board has also proposed increasing borrowing limits from Rs 300 Cr to Rs 1,000 Cr.
Confidence: HIGH
What changedThe company has committed to a massive greenfield expansion that will more than double its current manufacturing capacity and has significantly increased its debt headroom.
Why it mattersThis expansion signals high management confidence in future demand for specialty chemicals like SDAs and electrolyte salts. The doubling of capacity is a structural shift that could significantly re-rate the company's revenue potential if demand remains robust.
Proposed Capacity Addition: 344 KLExpansion vs Current Capacity: 122.8%Investment vs TTM Revenue: 40.3%New Borrowing Limit: Rs 1,000 CrQ1 Standalone PAT Growth (YoY): 103.6%Project Timeline: 21 months
📅 Short termThe stock is likely to react positively to the combination of strong Q1 earnings recovery and the announcement of a large-scale capacity expansion.
📈 Long termThe expansion provides a clear growth runway for the next 3-5 years. Success depends on the recovery of global demand for SDAs and the successful commercialization of new products in the supercapacitor segment.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk associated with a 21-month greenfield project
- Potential for increased interest costs given the higher borrowing limits
- Sensitivity to global demand for SDAs which impacted past margins
Key Highlights
Approved new greenfield unit at Dahej-III with 344 KL aggregate reactor capacity addition
Estimated investment of Rs 200 Cr to be funded via internal accruals and debt
Q1 FY27 standalone revenue grew 34.4% YoY to Rs 146.7 Cr from Rs 109.18 Cr
Proposed 233% increase in borrowing limits from Rs 300 Cr to Rs 1,000 Cr
Re-appointment of three founding promoters as MD and WTDs for 3-year terms starting Feb 2027
👀 What to Watch
Investors should monitor the execution timeline of the 21-month Dahej-III project and the ramp-up of the existing 280 KL capacity to see if it translates into the projected 27% growth rate.
Rs 200 Cr Greenfield Expansion: Tatva Chintan to Add 344 KL Capacity and Hike Borrowing Limits
Tatva Chintan has announced a major greenfield expansion at Dahej-III with an estimated investment of Rs 200 cr, aimed at adding 344 KL of specialty chemical capacity. This expansion is significant as it exceeds the company's current total capacity of 280 KL. To support this growth, the board approved increasing borrowing limits from Rs 300 cr to Rs 1,000 cr. Simultaneously, the company reported Q1 FY27 standalone revenue of Rs 146.7 cr, a 34% increase over the same quarter last year.
Confidence: HIGH
What changedThe company has initiated a massive capacity expansion phase and significantly increased its financial headroom for borrowing.
Why it mattersThe 344 KL addition is larger than the company's existing 280 KL capacity, suggesting a potential doubling of the revenue ceiling once fully operational and utilized.
Proposed Capex: Rs 200 crCapex vs TTM Revenue: 40.3%New Capacity Addition: 344 KLNew Borrowing Limit: Rs 1,000 crQ1 FY27 Standalone Revenue: Rs 146.7 cr
📅 Short termThe market is likely to react positively to the strong YoY revenue growth and the aggressive expansion plans.
📈 Long termThis is a structural growth move; if executed on time, it positions the company to capture significant market share in specialty chemicals over the next 3-5 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk associated with greenfield projects
- Potential for increased interest costs as borrowing limits are utilized
Key Highlights
Proposed greenfield capacity addition of 344 KL at Dahej-III, nearly doubling current 280 KL capacity
Estimated investment of Rs 200 cr for the new unit, representing ~40% of TTM revenue
Board approved a 233% increase in borrowing limits from Rs 300 cr to Rs 1,000 cr
Standalone Q1 FY27 revenue rose to Rs 146.7 cr from Rs 109.2 cr in Q1 FY26
Project execution timeline estimated at approximately 21 months
👀 What to Watch
Monitor the execution of the 21-month Dahej-III project and the impact of increased debt on the company's debt-to-equity ratio, which currently stands at a low 0.16.
Tatva Chintan Q1 PAT Doubles YoY; Announces Rs 200 Cr Greenfield Expansion
Tatva Chintan reported a strong Q1 FY27 with standalone revenue growing 34.4% YoY to Rs 146.70 Cr and PAT increasing 103.7% YoY to Rs 10.45 Cr. The board has approved a significant greenfield expansion at Dahej-III with an investment of Rs 200 Cr, which represents approximately 40% of its TTM revenue. To support this growth, the company is seeking shareholder approval to increase its borrowing limits from Rs 300 Cr to Rs 1,000 Cr. Additionally, the three founding promoter-directors have been re-appointed for three-year terms starting February 2027.
Confidence: HIGH
What changedThe company has transitioned from utilizing its recently expanded 280 KL capacity to initiating a massive 344 KL greenfield expansion and significantly raising its debt ceiling.
Why it mattersThe proposed 344 KL addition is larger than the company's entire current capacity, signaling a major structural scale-up and management's aggressive growth outlook for specialty chemicals.
Q1 Standalone Revenue: Rs 146.70 CrQ1 Standalone PAT: Rs 10.45 CrProposed Capex: Rs 200 CrCapex vs TTM Revenue: ~40.3%Proposed Capacity Addition: 344 KLNew Borrowing Limit: Rs 1,000 Cr
📅 Short termThe stock is likely to react positively to the strong YoY earnings recovery and the announcement of a large-scale capacity expansion.
📈 Long termThe doubling of capacity and massive increase in borrowing limits suggest the company is positioning for a significantly higher revenue base over the next 3-5 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk associated with a large greenfield project
- Potential for higher interest costs due to increased borrowing limits
- Global demand volatility for high-margin SDAs
Key Highlights
Standalone Revenue for Q1 FY27 rose to Rs 146.70 Cr, up from Rs 109.18 Cr in the same quarter last year.
Standalone PAT for the quarter stood at Rs 10.45 Cr, a 103.7% increase compared to Rs 5.13 Cr in Q1 FY26.
Approved a new greenfield unit at Dahej-III with a proposed capacity addition of 344 KL, exceeding the current 280 KL capacity.
Planned investment of approximately Rs 200 Cr for the expansion, to be funded via internal accruals and debt.
Proposed a 233% increase in borrowing limits to Rs 1,000 Cr to facilitate future capital requirements.
👀 What to Watch
Investors should monitor the execution timeline of the 21-month greenfield project and the impact of increased debt on the company's interest coverage ratios.
Tatva Chintan Promoters Declare Zero Share Encumbrance for FY 2025-26
Ajay Mansukhlal Patel, a promoter of Tatva Chintan Pharma Chem Limited, has submitted a declaration under Regulation 31(4) of SEBI Takeover Regulations. The declaration confirms that the promoter, along with persons acting in concert (PAC), has not created any direct or indirect encumbrance on their shares during the financial year ended March 31, 2026. This annual disclosure covers the main promoter and 10 other entities within the promoter group, including individuals and Star Enterprise. The filing provides transparency regarding the pledge status of the promoter holding.
Key Highlights
Declaration submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Promoters confirm zero direct or indirect encumbrance of shares during the financial year ended March 31, 2026.
The disclosure covers Ajay Mansukhlal Patel and 10 other listed entities/individuals within the promoter group.
A copy of the declaration has been forwarded to the Chairman of the Audit Committee of the company.
👀 What to Watch
Investors can view this as a positive confirmation of financial stability, as zero promoter share pledging reduces the risk of forced market liquidation. No immediate action is required other than noting the clean holding structure.
Tatva Chintan Q4 FY26: Revenue Up 24%, EBITDA Surges 214% to ₹281M; FY27 Growth Guided at 25%
Tatva Chintan reported a strong Q4 FY26 with operating revenue of INR 1,341 million, a 24% YoY increase, and EBITDA surging 214% YoY to INR 281 million. The company achieved a significant milestone by crossing INR 500 crores in annual revenue for FY26, driven by a massive recovery in Electrolyte Salts and steady SDA demand. Management has guided for a 25% revenue growth in FY27 with EBITDA margins expected between 20-22%, despite geopolitical headwinds and rising raw material costs. Key future growth drivers include the commercialization of semiconductor chemicals in Q1 FY27 and the groundbreaking of the Jolva greenfield project.
Key Highlights
Q4 FY26 Revenue grew 24% YoY to INR 1,341 million; EBITDA rose 214% YoY to INR 281 million.
Electrolyte Salts segment saw exceptional growth of 1,378% YoY, reaching INR 131 million in Q4.
Management maintains FY27 guidance of 25% revenue growth and 20-22% EBITDA margins.
Semiconductor chemicals segment achieved a milestone with first commercial dispatch scheduled for Q1 FY27.
Groundbreaking for the new Jolva greenfield facility is set for Q1 FY27 to drive growth from FY29.
👀 What to Watch
Investors should monitor the ramp-up in Electrolyte Salts and the successful commercialization of semiconductor chemicals as key catalysts for the guided 25% growth in FY27.
Tatva Chintan FY26 PAT Surges 636% to ₹421 Mn; Revenue Up 32% YoY
Tatva Chintan reported a strong financial recovery in FY26, with revenue growing 32% YoY to ₹5,059 million. Profitability saw a massive turnaround as PAT jumped 636% to ₹421 million, supported by EBITDA margins doubling from 8.9% to 18.4%. The growth was primarily driven by the Structure Directing Agents (SDA) segment, which now contributes 41% of total revenue, up from 31% in the previous year. The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.15x despite ongoing capital expenditure.
Key Highlights
FY26 Revenue from operations increased by 32% YoY to ₹5,059 million compared to ₹3,827 million in FY25.
EBITDA (excluding other income) grew by 172% YoY to ₹932 million, with margins expanding significantly to 18.4%.
Net profit (PAT) witnessed a massive 636% growth, reaching ₹421 million in FY26 versus ₹57 million in FY25.
SDA segment revenue grew substantially to ₹2,045 million, now representing 41% of the total revenue mix.
Q4 FY26 standalone performance was robust with revenue up 24% YoY and PAT surging 902% on a low base.
👀 What to Watch
Investors should note the sharp recovery in margins and the strong growth trajectory of the high-margin SDA segment. The company's leadership in green chemistry and electrolysis provides a competitive moat for long-term growth.
Tatva Chintan Recommends ₹2 Dividend; Appoints RSM Astute as Internal Auditor
Tatva Chintan Pharma Chem's Board has recommended a final dividend of ₹2 per share (20%) for the financial year 2025-26. The company has also announced key governance changes, appointing RSM Astute Consultech Private Limited as the Internal Auditor for FY 2026-27. Additionally, M/s. Zarna Thakar & Associates has been appointed as the Cost Auditor. These decisions were taken alongside the approval of the audited financial results for the quarter and year ended March 31, 2026.
Key Highlights
Recommended a final dividend of ₹2 per equity share (20% of face value) for FY 2025-26.
Appointed RSM Astute Consultech Private Limited, ranked among India's top 6 consulting groups, as Internal Auditor.
Appointed M/s. Zarna Thakar & Associates as Cost Auditor for the financial year 2026-27.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
The meeting concluded with a clean audit report from statutory auditors NDJ & CO. for the consolidated results.
👀 What to Watch
Investors should monitor the detailed FY26 financial performance for margin recovery trends while noting the positive step of hiring a top-tier internal audit firm. The dividend provides a modest yield for long-term holders.
Tatva Chintan Recommends ₹2 Final Dividend for FY 2025-26
The Board of Directors of Tatva Chintan Pharma Chem Limited has recommended a final dividend of ₹2 per equity share for the financial year ended March 31, 2026. This dividend represents a 20% payout on the face value of ₹10 per share and is subject to shareholder approval at the upcoming AGM. Alongside the dividend, the company approved its audited financial results for FY26 and appointed new internal and cost auditors for the 2026-27 fiscal year. The total equity share capital eligible for this dividend stands at approximately ₹23.39 crore.
Key Highlights
Recommended a final dividend of ₹2 per equity share (20% of face value) for FY 2025-26.
Total equity share capital involved is ₹23,39,20,550 comprising 2,33,92,055 shares.
Appointed RSM Astute Consultech Private Limited as Internal Auditor for FY 2026-27.
Appointed M/s. Zarna Thakar & Associates as Cost Auditor for the upcoming financial year.
Audited financial results for the quarter and full year ended March 31, 2026, have been approved.
👀 What to Watch
Investors should note the upcoming record date for the ₹2 dividend and review the full audited financial statements to assess the company's margin performance in the specialty chemicals sector.
Tatva Chintan Recommends ₹2 Final Dividend; Approves FY26 Audited Financial Results
Tatva Chintan Pharma Chem Limited has approved its audited financial results for the fiscal year ended March 31, 2026. The Board has recommended a final dividend of ₹2 per equity share (20% of face value), which is subject to shareholder approval. To strengthen its governance framework, the company has appointed RSM Astute Consultech as Internal Auditors and Zarna Thakar & Associates as Cost Auditors for the 2026-27 fiscal year. The consolidated financial results received an unmodified (clean) audit report from the statutory auditors.
Key Highlights
Recommended a final dividend of ₹2 per equity share (20% of face value) for FY 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Appointed RSM Astute Consultech Private Limited, a top 6 audit group in India, as Internal Auditor for FY 2026-27.
Appointed M/s. Zarna Thakar & Associates as Cost Auditor to audit cost records for the upcoming financial year.
The Board meeting concluded with a clean audit opinion on the consolidated financial statements.
👀 What to Watch
Investors should analyze the detailed P&L and balance sheet once published to evaluate margin trends in the specialty chemicals segment. The dividend recommendation indicates stable cash flows, but the stock's performance will likely depend on the underlying earnings growth figures.
Tatva Chintan Faces 20% Gas Supply Cut and New Pricing Mechanism Due to Government Order
Tatva Chintan Pharma Chem has been notified of a mandatory 20% reduction in natural gas supply following the 'Natural Gas (Supply Regulation) Order, 2026.' The government mandate, triggered by geopolitical conflicts in the Middle East, limits industrial supply to 80% of the past six months' average consumption. Furthermore, gas pricing will now be governed by a Pooled Price mechanism, which may lead to higher input costs. While the company is utilizing alternative fuels and optimizing processes, the full financial impact is currently unquantified.
Key Highlights
Natural gas supply capped at 80% of the average consumption of the previous six months.
Pricing shifted to a Pooled Price mechanism notified by the Petroleum Planning & Analysis Cell (PPAC).
Government mandate issued under the Essential Commodities Act, 1955, superseding existing gas contracts.
Company proactively adopting alternative fuel sources permitted by the Gujarat Pollution Control Board.
Order classified as a Force Majeure mitigation measure due to Middle East supply disruptions.
👀 What to Watch
Investors should monitor the company's gross margins in the coming quarters to assess the impact of higher pooled gas prices. Stay cautious as the duration of this supply disruption depends on geopolitical stability in the Middle East.
Tatva Chintan to Acquire 10.99% Stake in AMPIN C&I Power for ₹4 Crore
Tatva Chintan Pharma Chem Limited has entered into an agreement to acquire a 10.99% stake in AMPIN C&I Power Twenty Six Private Limited for ₹4 crore. This acquisition is part of a Group Captive Power Scheme aimed at sourcing 3.2 MW of solar and 3.2 MW of wind power for the company's operations. The move is strategically designed to reduce long-term energy costs and increase the share of renewable energy in its manufacturing processes. The target SPV is currently developing a hybrid power plant in Gujarat with a total capacity of 19.8 MW.
Key Highlights
Acquisition of 40,00,000 equity shares at ₹10 each, totaling an investment of ₹4 crore.
Secures long-term supply of 3.2 MW solar and 3.2 MW wind power under a captive consumption model.
The target SPV is setting up a hybrid plant with 9.9 MW Solar and 9.9 MW Wind capacity in Gir-Somnath, Gujarat.
Investment is intended to significantly reduce the company's energy costs and improve ESG compliance.
The acquisition will be completed in one or more tranches subject to regulatory approvals for open access.
👀 What to Watch
Investors should view this as a positive step toward operational efficiency and margin protection against rising energy costs. Monitor the project's commissioning timeline to assess when these cost savings will begin impacting the bottom line.
Tatva Chintan Q3 FY26 Revenue Surges 53% YoY to ₹1,313M; EBITDA Jumps 261%
Tatva Chintan reported a robust Q3 FY26 with operating revenue reaching ₹1,313 million, a 53% YoY increase, driven by a massive 86% growth in the Pharma & Agro segment. EBITDA witnessed a significant surge of 261% YoY to ₹255 million, reflecting improved operational efficiencies and a recovery in Structured Directing Agents (SDA). The company is set to break ground on a new greenfield facility at Jolva this quarter, focusing on high-value agro-intermediate import substitutes. Management indicated that validation trials for new capacities are scheduled to begin in mid-February 2026.
Key Highlights
Operating revenue grew 53% YoY to ₹1,313 million, with a 6% sequential improvement.
EBITDA increased by 261% YoY to ₹255 million, showing strong margin recovery and operational leverage.
Pharma, Agro & Specialty Chemicals segment revenue surged 86% YoY to ₹471 million.
Structured Directing Agents (SDA) revenue grew 65% YoY to ₹534 million despite a 10% sequential dip.
New greenfield project at Jolva, Dahej, to break ground in Q4 FY26 for agro-intermediate import substitution.
👀 What to Watch
Investors should focus on the successful ramp-up of the new Jolva facility and the upcoming validation trials in February as key growth catalysts. The strong recovery in the SDA and Agro segments suggests a fundamental turnaround, making the stock attractive for long-term portfolios.
Tatva Chintan Q3 FY26 PAT Surges to ₹152 Mn; Revenue Up 53% YoY with 19% EBITDA Margin
Tatva Chintan reported a robust financial recovery in Q3 FY26, with consolidated revenue growing 53% YoY to ₹1,313 million. Profitability saw a massive turnaround as PAT reached ₹152 million compared to a nominal ₹1 million in the same quarter last year. EBITDA margins expanded significantly to 19% from 8% YoY, driven by improved operational efficiencies and a favorable product mix. The Structure Directing Agents (SDA) segment continues to lead growth, contributing 41% to the total revenue for the nine-month period.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 53% YoY to ₹1,313 million, while 9M FY26 revenue rose 35% to ₹3,717 million.
EBITDA (excluding other income) for Q3 FY26 jumped 261% YoY to ₹255 million with margins improving to 19%.
Net Profit (PAT) for 9M FY26 stands at ₹317 million, a 578% increase compared to ₹47 million in 9M FY25.
Structure Directing Agents (SDA) segment remains the largest revenue contributor at 41%, followed by PASC at 34%.
Balance sheet remains strong with a low Debt-to-Equity ratio of 0.11x as of H1 FY26.
👀 What to Watch
The company has demonstrated a significant operational turnaround with sharp margin expansion and profit growth. Investors should maintain a positive outlook while monitoring the sustainability of demand in the SDA and PTC segments.
Tatva Chintan Q3 FY26 Net Profit Jumps to ₹151.65M; Revenue Grows 53% YoY
Tatva Chintan reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 53% YoY to ₹1,313.34 million. The company achieved a significant turnaround in profitability, posting a net profit of ₹151.65 million compared to just ₹1.38 million in the same quarter last year. On a nine-month basis, the net profit reached ₹317.33 million, a substantial jump from ₹46.83 million in 9M FY25. This growth was supported by a recovery in the specialty chemicals segment and improved operational efficiencies.
Key Highlights
Consolidated Revenue from operations increased 52.9% YoY to ₹1,313.34 million.
Net Profit witnessed a massive surge to ₹151.65 million from ₹1.38 million in Q3 FY25.
Profit Before Tax (PBT) turned positive at ₹176.58 million versus a loss of ₹2.35 million YoY.
9M FY26 Revenue grew to ₹3,717.04 million, up from ₹2,748.50 million in the previous year.
Earnings Per Share (EPS) for the quarter stood at ₹6.48, compared to ₹0.06 in the year-ago period.
👀 What to Watch
The sharp recovery in both top-line and bottom-line suggests a strong demand environment and operational turnaround, making it a positive signal for long-term investors. Investors should monitor the sustainability of these margins as the broader specialty chemicals industry continues its recovery.
